This is a working overview of reversed-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-03. Anything still debated is marked as such rather than presented as settled.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular weight | Approximately 1024 g/mol | Calculated for the free base |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and polar solvents | Poorly soluble in non-polar solvents |
| Typical storage | -20 degrees Celsius, dry, protected from light | Refers to the solid form |
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
In 2010, the company and Sanofi-Aventis created an outsourcing partnership, which, at the time was considered the largest between a contract research organization and a pharmaceutical company. Covance also acquired sites from Sanofi-Aventis in Porcheville, France and Alnwick, United Kingdom. In 2014, the company acquired Medaxial, a London-based value communication consultancy. In February 2015, Labcorp acquired Covance for $6.1 billion in cash and stock. In 2016, the company entered into a strategic alliance with Global Specimen Solutions, in which the company offered GSS products GlobalCODE and snapTRACK to its clients. In December 2017, Covance acquired the company. In September 2017, the company acquired Chiltern, a specialty contract research organization, for $1.2 billion in cash. In June 2018, the company acquired Sciformix Corporation, a scientific process outsourcing company focused on pharmacovigilance and regulatory issues for biopharmaceutical and medical devices clients. In August 2018, Covance Food Solutions was sold to Eurofins Scientific for $670 million. In June 2019, the company acquired the nonclinical contract research services business of Envigo (now Inotiv), which acquired the research products business of the company. In the first quarter of 2019, the company spent $47 million to acquire MI Bioresearch, a provider of preclinical capabilities in cell and gene therapy and oncology testing, and Regulatory and Clinical Research Institute (RCRI), a device-focused contract research organization.
The other two electric utility companies in the country are Sarawak Energy and Sabah Electricity. In 2013, Malaysia's total power generation capacity was over 29,728 megawatts. Total electricity generation was 140,985.01 GWh and total electricity consumption was 116,087.51 GWh. Energy production in Malaysia is largely based on oil and natural gas, owing to Malaysia's oil and natural gas reserves, which are the fourth largest in the Asia-Pacific region.
The three substrates of the enzyme are dopamine, vitamin C (ascorbate), and O2. The products are norepinephrine, dehydroascorbate, and H2O. DBH is a 290-kDa copper-containing oxygenase consisting of four identical subunits, and its activity requires ascorbate as a cofactor. It is the only enzyme involved in the synthesis of small-molecule neurotransmitters that is membrane-bound, making norepinephrine the only known transmitter synthesized inside vesicles. It is expressed in noradrenergic neurons of the central nervous system (i.e., locus coeruleus) and peripheral nervous systems (i.e., sympathetic ganglia), as well as in chromaffin cells of the adrenal medulla.
=== Other === The muscles that control breathing and limb movements can also be affected; rarely do these present as the first symptoms of myasthenia gravis, but develop over months to years. In a myasthenic crisis, a paralysis of the respiratory muscles occurs, necessitating assisted ventilation to sustain life. Crises may be triggered by various biological stressors such as infection, fever, an adverse reaction to medication, or emotional stress.
Sources: en.wikipedia.org
68Ga-Trivehexin is a radiotracer for positron emission tomography (PET), obtained by labeling the peptide conjugate Trivehexin (INN: relitegatide brexetan) with the positron emitting radionuclide gallium-68 (68Ga). 68Ga-Trivehexin targets (i.e., binds to) the cell surface receptor αvβ6-integrin and accumulates in αvβ6-integrin-abundant tissues after intravenous (i.v.) application. 68Ga-Trivehexin is thus applied for PET imaging of medical conditions associated with elevated αvβ6-integrin expression. αvβ6-Integrin, the biological target of 68Ga-Trivehexin, is a heterodimeric transmembrane cell adhesion receptor whose primary natural ligand is latency associated peptide (LAP) in its complex with transforming growth factor beta 1 (TGF-β1). Binding of αvβ6-integrin to LAP releases and thus, activates TGF-β1. In early-stage cancer, TGF-β1 acts as a tumor suppressor but can turn into a tumor promoter as cancers develop, and furthermore induces fibrosis, particularly of the lung. As the likely most important activator of TGF-β1, αvβ6-integrin is often found overexpressed in tumors and fibrosis, which is why 68Ga-Trivehexin PET imaging is primarily relevant in this medical context.
During the 80th session of the UN General Assembly in September 2025, Trump met in New York a group of leaders of several Arab states to discuss the situation of the Gaza Strip. Reportedly, he presented them with a 21-point plan that called for ending the war and ending Hamas rule over the strip while establishing an international Arab military force to control the area for a period of three years. He also assured them that he would not allow Israel to annex the West Bank. In late September 2025, Israeli and British media reported a proposal by former British prime minister Tony Blair for a Gaza International Transitional Authority to administer the Gaza Strip for a transitional period, before turning over administration to the Palestinian Authority.
There is no disease-modifying treatments proven to cure Alzheimer's disease, and because of this, AD research has focused on interventions to prevent the onset and progression. There is no evidence that supports any particular measure in preventing AD, and studies of measures to prevent the onset or progression have produced inconsistent results. Epidemiological studies have proposed relationships between an individual's likelihood of developing AD and modifiable factors, such as medications, lifestyle, and diet. There are some challenges in determining whether interventions for AD act as a primary prevention method, preventing the disease itself, or a secondary prevention method, identifying the early stages of the disease. These challenges include duration of intervention, different stages of disease at which intervention begins, and lack of standardization of inclusion criteria regarding biomarkers specific for AD. Further research is needed to determine factors that can help prevent AD.
== Plot == Jesse (Danny McBride), Judy (Edi Patterson) and Kelvin (Adam DeVine) participate in a rehearsal for the "Aimee-Leigh Birthday Celebration Give-A-Thon", hosted by Baby Billy (Walton Goggins). However, during their attempt to lift up, the Gemstones' jet packs malfunction and ruin part of the set. Billy scolds them and demands that they find Eli, who has gone missing for the past few days, as he is vital to the Give-A-Thon's success. Eli (John Goodman) has moved to Florida, living in a yacht where he drinks alcohol and has sex with strangers. Jesse, Judy and Kelvin arrive to get him to take part in the telethon, but Eli refuses, feeling he needs time to consider what he truly wants in life. Nevertheless, they force him to change his mind after repeating the word "pussy" to annoy him. BJ (Tim Baltz) now attends pole dancing classes, although Judy feels jealous of his female colleagues. Kelvin and Keefe (Tony Cavalero) have embraced their relationship and formed a new church program named "Prism", although Keefe wishes they would finally marry or kiss in public. The Gemstones have also launched "Prayer Pods" to the market, but sales are incredibly low. Billy surprises the family by bringing Lori Milsap (Megan Mullally), Aimee-Leigh's long-time musical partner. She and Eli bond, reminiscing over their experiences with Aimee-Leigh. During the telethon, Eli is amazed upon seeing Lori singing, and has a flirtatious encounter with her backstage.
When finally arrested and taken to detention by the Americans, the ‘pineapple’ moniker resurfaced in the form of an oft heard chant "the Pineapple’s in the can". He lived a lavish lifestyle during his time as the de facto ruler of Panama, described in an obituary as a "libertine life off drug-trade riches, complete with luxurious mansions, cocaine-fueled parties and voluminous collections of antique guns". His bravado during public speeches was remarked upon by commentators; for instance, after his indictment in the U.S., he made a public speech while brandishing a machete, and declaimed "Not one step back!" The attitude of machismo that Noriega adopted has been described as a reaction to the persecution which his half-brother Luis faced as an openly homosexual man in Panama and Peru. This image of strength contrasted sharply with the impact of a mug shot which was taken of him after his capture, and the photo became a symbol of his fall from power. He was described as a deeply superstitious man, who placed trust in a number of talismans which he carried with him. Guy Debord wrote that Noriega's career exemplified a path to power for rulers in his era, calling him "a sort of statesman in a sort of state, a sort of general, a capitalist... who sells everything and fakes everything, in a world which does precisely the same thing." His capture received renewed media attention when on the exact same day, 36 years later, Venezuelan president Nicolás Maduro was abducted by the same U.S. government agency under similar reasoning.
Sources: en.wikipedia.org
== Life cycle == Like many species of bamboo, black bamboo synchronizes its flowering, with flowering events happening every 40-120 years. According to one source, it has bloomed every 120 years "since records have been kept". It is monocarpic, that is, after flowering, the plants die. Henon bamboo flowers every 120 years and is predicted to flower in the 2020s. Since it is widely distributed in Japan, dieback of its stands may cause serious social and environmental problems. Moreover, Henon bamboo rarely sets fertile seeds, so it is not clear how this species has survived over long periods in Japan.
== Structure == STAT5a shares the same six functional domains as the other members of the STAT family. It contains 20 amino acids unique to its C-terminal domain and is 96% similar to its homolog, STAT5b. The six functional domains and their corresponding amino acid positions are as follows:
Competition law aims "to prevent competition from being distorted to the detriment of the public interest, individual undertakings and consumers", especially by limiting big business power. It covers all types of enterprise or "undertaking" regardless of legal form, or "every entity engaged in an economic activity", but not non-profit organisations based on the principle of solidarity, or bodies carrying out a regulatory function. Employees and trade unions are not undertakings, and are outside the scope of competition law, and so are solo self-employed workers, because on long-standing consensus in international law labour is not a commodity, and workers have structurally unequal bargaining power compared to business and employers. A legal professional body setting regulatory standards was held to be outside competition law, and so were the rules of the International Olympic Committee and the International Swimming Federation in prohibiting drugs, because although drugs might increase "competition", the "integrity and objectivity of competitive sport" was more important. EU competition law only regulates activities where trade between member states is affected to an "appreciable" degree, but member states may have higher standards that comply with social objectives. The four most important sets of rules relate to monopolies and enterprises with a dominant position, mergers and takeovers, cartels or collusive practices, and state aid.
== Epidemiology == Incidence of DM peaks at ages 40–50, but the disease can affect people of all ages. It tends to affect more women than men. The prevalence of DM ranges from one to 22 per 100,000 people.
Sources: en.wikipedia.org
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.
Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.
Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.